Nicotinic acetylcholine receptor ligands as potential therapeutics

Bibliography

• ARNERIC SP, BRIONI JD (Eds): Neuronal Nicotinic Receptors. J. Wiley 6c Sons. New York (1999).
   Google Scholar
• LUKAS RJ, CHANGEUX JP, NOVERE NL et al.: International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev. (1999) 51:397–401.
   Google Scholar
• SARGENT PB: The diversity of neuronal nicotinic acetylcholine receptors. Ann. Rev. Neurosci. (1993) 16:403–443.
   PubMed Web of Science ®Google Scholar
• BERTRAND D, CHANGEUX JP: Nicotinic receptor: an allosteric protein specialized for intracellular communication. Semin. Neurosci. (1995) 7:75–90.
   Google Scholar
• LE NOVÉRE N, CHANGEUX JP: Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J. Mot Eva (1995) 40:155–172.
   PubMed Web of Science ®Google Scholar
• LUSTIG LR, PENG H, HIEL H, YAMAMOTO T, FUCHS PA: Molecular cloning and mapping of the human nicotinic acetylcholine receptor am (CHRNA 10). Genomics (2001) 73:272–283.
   PubMed Web of Science ®Google Scholar
• •This paper reports about a new subunit.
   Google Scholar
• CHANGEUX JP, EDELSTEIN SJ: Allosteric receptors after 30 years. Neuron (1998) 21:959–980.
   PubMedGoogle Scholar
• BUNNELLE WH, DART MJ, SCHRIMPF MR: Design of ligands for the nicotinic acetylcholine receptors: the quest for selectivity. Curr. Topics Med. Chem. (2004) 4:299–334.
   PubMed Web of Science ®Google Scholar
• •Exhaustive review on nAChR ligands
   Google Scholar
• GRANDO SA: Biological functions ofkeratinocyte cholinergic receptors. Investig. Dermatol Symp. Proc. (1997) 2:41–48.
   PubMedGoogle Scholar
• MAUS AD, PEREIRA EF, KARACHUNSKI PI et al.: Human and rodent bronchial epithelial cells express functional nicotinic acetylcholine receptors. Mol Pharmacol (1998) 54:779–788.
   PubMed Web of Science ®Google Scholar
• NGUYEN VT, HALL LL, GALLAGHER G et al.: Choline acetyltransferase, acetylcholinesterase, and nicotinic acetylcholine receptors of human gingival and esophageal epithelia. J. Dent. Res. (2000) 79:939–949.
   PubMedGoogle Scholar
• SKOK MV, KALASHNIK EN, KOVAL LN et al.: Functional nicotinic acetylcholine receptors are expressed in B lymphocyte-derived cell lines. MoL Pharmacol (2003) 64:885–889.
   PubMedGoogle Scholar
• ELGOYHEN AB, VETTER DE, KATZ E, ROTHLIN CV, HEINEMANN SF, BOULTER J: al,: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc. Natl. Acad. Sci. USA (2001) 98:3501–3506.
   PubMed Web of Science ®Google Scholar
• BAKER ER, ZWART R, SHER E, MILLAR NS: Pharmacological properties of a9a10 nicotinic acetylcholine receptors revealed by heterologous expression of subunit chimeras. MoL PharmacoL (2004) 65:453–460.
   PubMed Web of Science ®Google Scholar
• ELGOYHEN AB, JOHNSON DS, BOULTER J, VETTER DE, HEINEMANN S: a9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell (1994) 79:705–715.
   PubMed Web of Science ®Google Scholar
• LABARCA C, SCHWARZ J, DESHPANDE P et al.: Point mutant mice with hypersensitive a, nicotinic receptors show dopaminergic deficits and increased anxiety. Proc. Nail. Acad. Sci. USA (2001) 98:2786–2791.
   PubMed Web of Science ®Google Scholar
• PICCIOTTO MR, ZOLI M, LENA C et al.: Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature (1995) 374:65–67.
   PubMed Web of Science ®Google Scholar
• MARUBIO LM, DEL MAR ARROYO-JIMENEZ M et al.: Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature (1999) 398:805–810.
   Google Scholar
• ROSS SA, WONG JY, CLIFFORD JJ et al.: Phenotypic characterization of an a, neuronal nicotinic acetylcholine receptor subunit knock-out mouse. J. Neurosci. (2000) 20:6431–6441.
   PubMed Web of Science ®Google Scholar
• CHAMPTIAUX N, HAN ZY, BESSIS A et al.: Distribution and pharmacology of a6-containing nicotinic acetylcholine receptors analyzed with mutant mice. J. Neurosci. (2002) 22:1208–1217.
   PubMedGoogle Scholar
• XU W, GELBER S, ORR-URTREGER A et al.: Megacystis, mydriasis, and ion channel defect in mice lacking the a, neuronal nicotinic acetylcholine receptor. Proc. Nail. Acad. Sci. USA (1999) 96:5746–5751.
   PubMed Web of Science ®Google Scholar
• WANG N, ORR-URTREGER A, CHAPMAN J, RABINOWITZ R, NACHMAN R, KORCZYN AD: Autonomic function in mice lacking a5 neuronal nicotinic acetylcholine receptor subunit. J. PhysioL (2002) 542:347–354.
   PubMed Web of Science ®Google Scholar
• FRANCESCHINI D, PAYLOR R, BROIDE R et al.: Absence of arcontaining neuronal nicotinic acetylcholine receptors does not prevent nicotine-induced seizures. Brain Res. MoL Brain Res. (2002) 98:29–40.
   PubMedGoogle Scholar
• VETTER DE, LIBERMAN MC, MANN J et al.: Role of a9 nicotinic ACh receptor subunits in the development and function of cochlear efferent innervation. Neuron (1999) 23:93–103.
   PubMed Web of Science ®Google Scholar
• ZOLI M, LENA C, PICCIOTTO MR, CHANGEUX JP: Identification of four classes of brain nicotinic receptors using f32 mutant mice. J. Neurosci. (1998) 18:4461–4472.
   PubMed Web of Science ®Google Scholar
• XU W, ORR-URTREGER A, NIGRO F et al.: Multiorgan autonomic dysfunction in mice lacking the f32 and the 134 subunits of neuronal nicotinic acetylcholine receptors. Neurosci. (1999) 19:9298–9305.
   Google Scholar
• ZOLI M, PICCIOTTO MR, FERRARI R, COCCHI D, CHANGEUX JP: Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors. EMBO (1999) 18:1235–1244.
   PubMedGoogle Scholar
• PICCIOTTO MR, ZOLI M, RIMONDINI R et al.: Acetylcholine receptors containing the f32 subunit are involved in the reinforcing properties of nicotine. Nature (1998) 391:173–177.
   PubMed Web of Science ®Google Scholar
• BOYD RT: The molecular biology of neuronal nicotinic acetylcholine receptors. Crit. Rev. ToxicoL (1997) 27:299–318.
   PubMed Web of Science ®Google Scholar
• LEWIS TM, HARKNESS PC, SIVILOTTI LG, COLQUHOUN D, MILLAR NS: The ion channel properties of a rat recombinant neuronal nicotinic receptor are dependent on the host cell type. PhysioL (1997) 1:299–306.
   Google Scholar
• TRUONG A, XING X, FORSAYETH JR, DWOSKIN LP, CROOKS PA, COHEN BN: Pharmacological differences between immunoisolated native brain and heterologously expressed rat a132 nicotinic receptors. Brain Res. MoL Brain Res. (2001) 96:68–76.
   PubMedGoogle Scholar
• LENA C, CHANGEUX JP: Pathologicalmutations of nicotinic receptors and nicotine-based therapies for brain disorders. Curr. Opin. NeurobioL (1997) 7:674–82.
   PubMedGoogle Scholar
• JONES S, SUDWEEKS S, YAKEL JL: Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci. (1999) 22:555–561.
   PubMed Web of Science ®Google Scholar
• LLOYD GK, WILLIAMS M: Neuronal nicotinic acetylcholine receptors as novel drug targets. J. PharmacoL Exp. Ther. (2000) 292:461–467.
   PubMed Web of Science ®Google Scholar
• PETO R, LOPEZ AD, BOREHAM J, THUN M, HEATH C JR, DOLL R: Mortality from smoking worldwide. Br. Med. Bull. (1996) 52:12–21.
   PubMed Web of Science ®Google Scholar
• HENNINGFIELD JE, MIYASATO K, JASINSKI DR: Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. PharmacoL Exp. Ther. (1985) 234:1–12.
   PubMed Web of Science ®Google Scholar
• DANI JA, JI D, ZHOU FM: Synaptic plasticity and nicotine addiction. Neuron (2001) 31:349–352.
   PubMedGoogle Scholar
• GENTRY CL, LUKAS RJ: Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. Curr. Drug Target CNS NeuroL Disord. (2002) 1:359–385.
   PubMedGoogle Scholar
• TERRY AV BUCCAFUSCO JJ: The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. PharmacoL Exp. Ther. (2003) 306:821–827.
   PubMedGoogle Scholar
• PERRY E, MARTIN-RUIZ C, LEE M et al.: Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur. j PharmacoL (2000) 393:215–222.
   PubMed Web of Science ®Google Scholar
• -WHITEHOUSE PJ, MARTINO AM, WAGSTER MV et al.: Reductions in [3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study. Neurology (1988) 38:720–723.
   PubMedGoogle Scholar
• SCHRODER H, GIACOBINI E, STRUBLE RG, ZILLES K, MAELICKE A: Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease. NeurobioL Aging (1991) 12:259–262.
   PubMed Web of Science ®Google Scholar
• QUIK M, JEYARASASINGAM G: Nicotinic receptors and Parkinson's disease. Eur. J. Pharmacol. (2000) 393:223–230.
   PubMedGoogle Scholar
• QUIK M: Smoking, nicotine and Parkinson's disease. Trends Neurosci. (2004) 27:561–568.
   PubMedGoogle Scholar
• QUIK M, VAILATI S, BORDIA T et aL:Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methy1-4-pheny1-1,2,3,6-tetrahydropyridine or L-DOPA. Mol. PharmacoL (2005) 67:32–41.
   PubMedGoogle Scholar
• COURT J, SPURDEN D, LLOYD Set aL: Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: a-bungarotoxin and nicotine binding in the thalamus. J. Neurochem. (1999) 73:1590–1597.
   PubMed Web of Science ®Google Scholar
• SILVER AA, SHYTLE RD, PHILIPP MK, WILKINSON BJ, MCCONVILLE B, SANBERG PR: Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. J. Clin. Psychiatry (2001) 62:707–714.
   PubMed Web of Science ®Google Scholar
• SANBERG PR, FOGELSON HM, MANDERSCHEID PZ, PARKER KW, NORMAN AB, MCCONVILLE BJ: Nicotine gum and haloperidol in Tourette's syndrome. Lancet (1988) 1:592.
   PubMedGoogle Scholar
• SANBERG PR, SILVER AA, SHYTLE RD et al.: Nicotine for the treatment of Tourette's syndrome. PharmacoL Ther. (1997) 74:21–25.
   PubMed Web of Science ®Google Scholar
• SANBERG PR, SHYTLE RD, SILVER AA: Treatment of Tourette's syndrome with mecamylamine. Lancet (1998) 352:705–706.
   PubMed Web of Science ®Google Scholar
• DALACK GW, MEADOR-WOODRUFF JH: Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schizophr. Res. (1996) 22:133–141.
   PubMed Web of Science ®Google Scholar
• FREEDMAN R, HALL M, ADLER LE, LEONARD S: Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Bia Psychiatry (1995) 38:22–33.
   PubMed Web of Science ®Google Scholar
• FREEDMAN R, COON H, MYLES-WORSLEY M et al.: Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Nail. Acad. Sci.USA (1997) 94:587–592.
   PubMed Web of Science ®Google Scholar
• LEONARD S, BREESE C, ADAMS C et al.: Smoking and schizophrenia: abnormal nicotinic receptor expression. Eur. PharmacoL (2000) 393:237–242.
   PubMed Web of Science ®Google Scholar
• STEINLEIN OK, MULLEY JC, PROPPING P et al.: A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat. Genet. (1995) 11:201–203.
   PubMed Web of Science ®Google Scholar
• STEINLEIN OK: Neuronal nicotinic receptors in human epilepsy. Eur. J. PharmacoL (2000) 393:243–247.
   PubMed Web of Science ®Google Scholar
• SCHEFFER IE, BHATIA KP, LOPES-CENDES I et al.: Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder. Lancet (1994) 343:515–517.
   PubMed Web of Science ®Google Scholar
• COVEY LS, GLASSMAN AH, STETNER F: Cigarette smoking and major depression. J. Addict. Dis. (1998) 17:35–46.
   PubMed Web of Science ®Google Scholar
• BADIO B, DALY JW: Epibatidine, a potent analgetic and nicotinic agonist. MoL PharmacoL (1994) 45:563–569.
   PubMed Web of Science ®Google Scholar
• DECKER MW, CURZON P, HOLLADAY MW et al.: The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594. J. PhysioL Paris (1998) 92:221–224.
   PubMedGoogle Scholar
• BERNIK TR, FRIEDMAN SG, OCHANI M et al.: Pharmacological stimulation of the cholinergic antiinflammatory pathway. J. Exp. Med. (2002) 195:781–788.
   PubMed Web of Science ®Google Scholar
• WANG H, YU M, OCHANI M et aL: Nicotinic acetylcholine receptor a, subunit is an essential regulator of inflammation. Nature (2003) 421:384–388.
   PubMed Web of Science ®Google Scholar
• JICK H, WALKER AM: Cigarette smoking and ulcerative colitis. N EngL J. Med. (1983) 308:261–263.
   PubMed Web of Science ®Google Scholar
• GUSLANDI M: Nicotine treatment for ulcerative colitis. Br. J. Clin. PharmacoL (1999) 48:481–484.
   PubMedGoogle Scholar
• THOMAS GA, RHODES J, GREEN J: Nicotine and gastrointestinal disease. QJM (1996) 89:485–488.
   PubMedGoogle Scholar
• GALEAZZI F, BLENNERHASSETT PA, QIU B, O'BYRNE PM, COLLINS SM: Cigarette smoke aggravates experimental colitis in rats. Gastroenterology (1999) 117:877–883.
   PubMed Web of Science ®Google Scholar
• THOMAS GA, RHODES J, GREEN JT, RICHARDSON C: Role of smoking in inflammatory bowel disease: implications for therapy. Postgrad. Med. J. (2000) 76:273–279.
   PubMed Web of Science ®Google Scholar
• MCGEHEE DS, HEATH MJ, GELBER S, DEVAY P, ROLE LW: Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science (1995) 269:1692–1696.
   PubMed Web of Science ®Google Scholar
• GRAY R, RAJAN AS, RADCLIFFE KA, YAKEHIRO M, DANI JA: Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature (1996) 383:713–716.
   PubMed Web of Science ®Google Scholar
• BUNNELLE WH, DECKER MW: Neuronal nicotinic acetylcholine receptor ligands as potential analgesics. Expert Opin. Ther. Patents (2003) 13:1003–1021.
   Web of Science ®Google Scholar
• TOMA L, BARLOCCO D, GELAIN A: Neuronal nicotinic acetylcholine receptor agonists. Expert Opin. Ther. Patents (2004) 14:1029–1040.
   Web of Science ®Google Scholar
• PAPKE RL, BENCHERIF M, LIPPIELLO P: An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the a, subtype. Neurosci. Lett. (1996) 213:201–204.
   PubMed Web of Science ®Google Scholar
• BEENE DL, BRANDT GS; ZHONG W, ZACHARIAS NM, LESTER HA, DOUGHERTY DA: Cation-pi interactions in ligand recognition by serotonergic (5-HT3A) and nicotinic acetylcholine receptors: the anomalous binding properties of nicotine. Biochem. (2002) 41:10262–10269.
   PubMed Web of Science ®Google Scholar
• BEERS WH, REICH E: Structure and activity of acetylcholine. Nature (1970) 228:917–922.
   PubMed Web of Science ®Google Scholar
• SHERIDAN RP, NILAKANTAN R, DIXON JS, VENKATARAGHAVAN R: The ensemble approach to distance geometry: application to the nicotinic pharmacophore. J. Med. Chem. (1986) 29:899–906.
   PubMed Web of Science ®Google Scholar
• HOLLADAY MW, DART MJ, LYNCH JK: Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J. Med. Chem. (1997) 40:4169–4194.
   PubMed Web of Science ®Google Scholar
• GLENNON RA, HERNDON JL, DUKAT M: Epibatidine-aided studies toward definition of a nicotine receptor pharmacophore. Med. Chem. Res. (1994) 4:461–473.
   Google Scholar
• SCHMITT JD: Exploring the nature of molecular recognition in nicotinic acetylcholine receptors. Curr. Med. Chem. (2000) 7:749–800.
   PubMed Web of Science ®Google Scholar
• •Exhaustive review on nAChR ligands.
   Google Scholar
• NICOLOTTI 0, ALTOMARE C, PELLEGRINI-CALACE M, CAROTTI Neuronal nicotinic acetylcholine receptor agonists: pharmacophores, evolutionary QSAR and 3D-QSAR models. Cuff. Topics Med. Chem. (2004) 4:335–360.
   PubMed Web of Science ®Google Scholar
• GLENNON RA, MALGORZATA D, LIANG L: Musings on a402 nicotinic acetylcholine (nACh) receptor pharmacophore models. Curr. Topics Med. Chem. (2004) 4:631–644.
   PubMedGoogle Scholar
• GLENNON RA, DUKAT M: a4132 nACh receptor pharmacophore models. Bioorg. Med. Chem. Lett. (2004) 19:1841–1844.
   Google Scholar
• TONDER JE, OLESEN PH, HANSEN JB, BEGTRUP M, PETTERSSON I: An improved nicotinic pharmacophore and a stereoselective CoMFA-model for nicotinic agonists acting at the central nicotinic acetylcholine receptors. J. Comput. Aided MoL Des. (2001) 15:247–258.
   PubMedGoogle Scholar
• MULLEN G, NAPIER J, BALESTRA M et al.: (-)-Spiro [1-azabicyclo [2.2.2] octane-3,5'-ozazolidin-2'-one], a conformationally restricted analogue of acetylcholine, is a highly selective fidl agonist at the a7 nicotinic acetylcholine receptor. J. Med. Chem. (2000) 43:4045–4050.
   Google Scholar
• BROAD LM, FELTHOUSE C, ZWART R et al.: PSAB-OFP, a selective a7 nicotinic receptor agonist, is also a potent agonist of the 5-HT3 receptor. Eur. j PharmacoL (2002) 452:137–144.
   PubMed Web of Science ®Google Scholar
• BITON B, BERGIS OE, GALLI F et al.: SSR180711A, a novel selective a7 nicotinic receptor partial agonist. I. Binding profile and in vitro functional characterization. Soc. Neurosci. Meeting (2004) Abst. 583.1.
   Google Scholar
• BERGIS OE, PICHAT P, SANTAMARIA R et ell.: 55R180711A, a novel selective a7 nicotinic receptor partial agonist. II. Effects in models predictive of therapeutic activity on cognitive symptoms of Alzheimer's disease. Soc. Neurosci. Meeting (2004) Abst. 583.2.
   Google Scholar
• PICHAT P, BERGIS OE, TERRANOVA JP et al.: 55R180711A, a novel selective a7 nicotinic receptor partial agonist. III. Effects in models predictive of therapeutic activity on cognitive symptoms of schizophrenia. Soc. Neurosci. Meeting (2004) Abst. 583.3.
   Google Scholar
• VIGE X, COSTE A, DE-GALLIER T, MARC C, OURY-DONAT F: 55R180711A, a novel selective a7 nicotinic receptor partial agonist. IV. Up-regulation of a7 nicotinic acetylcholine receptors in vitro and in vivo. Soc. Neurosci. Meeting (2004) Abst. 583.4.
   Google Scholar
• HAUSER TA, GATTO GJ, JORDAN KG, LETCHWORTH SR, PAPKE RL, BENCHERIF M: TC-5280, a full a7 nicotinic acetylcholine receptor agonist, attenuates deficits in step - through passive avoidance and prepulse inhibition in rats. Soc. Neurosci. Meeting (2004) Abst. 435.13. Patents
   Google Scholar